Virtus Fund Advisers’s Juno Therapeutics, Inc. JUNO Stock Holding History

Virtus Fund Advisers’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$359K	Buy	+7,860	New	+$392K	﹤0.01%	389

Other funds holding JUNO

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Virtus Fund Advisers's JUNO Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Juno Therapeutics, Inc. (JUNO) in Q4 2017: 7,860 shares worth $359K. The stake represents ﹤0.01% of the portfolio and ranks #389 among its holdings.

237 funds tracked by Wall St. Rank hold JUNO as of Q4 2017.

Virtus Fund Advisers held 7,860 shares of Juno Therapeutics, Inc. worth $359K as of Q4 2017.
Juno Therapeutics, Inc. was a new Virtus Fund Advisers position in Q4 2017.
Juno Therapeutics, Inc. made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #389 holding.
237 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.